Top Industry Leaders in the Actinic Keratosis Treatment Market
Latest Actinic Keratosis Treatment Companies Update:
Biofrontera AG commercially launches AMELUZ in Finland: This product approval expands Biofrontera's reach in Europe and offers an alternative to traditional photodynamic therapy with its BF-RhodoLED lamp
Almirall receives FDA approval for Klisyri (tirbanibulin): This new topical cream offers a once-daily application option for AK treatment, potentially improving patient compliance.
Cipher Pharmaceuticals Inc. expands distribution of Zyclara® (imiquimod): This established topical cream sees continued market penetration, solidifying its position in the AK treatment landscape.
Sun Pharmaceutical Industries Ltd. acquires Taro Pharmaceuticals Holdings Inc.: This acquisition consolidates Sun Pharma's position in the dermatology market, potentially impacting AK treatment offerings.
Valeant Pharmaceuticals announces positive Phase 3 results for Duavlir (alimetinib/ingenol mebutate): This investigational topical gel demonstrates promising efficacy and safety in AK treatment, potentially entering the market soon.
List of Actinic Keratosis Treatment Key companies in the market
- Stanford Chemicals (US)
- Alma Lasers (Israel),
- 3M (US),
- Sun Pharmaceutical Industries Ltd. (India),
- Galderma S.A (Switzerland),
- Leo Pharma (Denmark),
- Valeant Pharmaceuticals (US),
- BioLineRx (Israel),
- Cipher Pharmaceuticals Inc (Canada),
- Biofrontera AG (Germany)